NSPR InspireMD Inc
NSPR $2.43
$0.00
·Closed $2.39
$0.04
(1.67%)
After Hours
Updated: 11:55 PM UTC
| 34,603 |
Mkt Cap
$100.55MVolume
57,478.0052W High
$3.8052W Low
$1.99PE Ratio
-2.90NSPR Fundamentals
Price
$2.39Prev Close
$2.41Open
$2.4250D MA
$2.45Beta
0.17Avg. Volume
112,538.24EPS (Annual)
-$0.7633P/B
3.88Rev/Employee
$81,500.00CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·3mo ago
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.
Zacks·3mo ago
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
Globe Newswire·2y ago
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
Globe Newswire·2y ago
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company's ongoing U.S. Investigational Device...
Globe Newswire·2y ago
Avance de ganancias de InspireMD
El mi rcoles, 06 de marzo, InspireMD (NASDAQ:NSPR) publicar su ltimo informe de ganancias. Analiza la noticia con ayuda de Benzinga.
Ingresos netos, ganancias y beneficios por acci n
Las ganancias...
Benzinga·2y ago
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard...
Globe Newswire·2y ago
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System
Development of SwitchGuard consistent with Company's mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class...
Globe Newswire·2y ago
InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework
TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke...
Globe Newswire·2y ago
Neutral
48
Normal
54
Latest NSPR News
ViewCVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
Zacks·3mo ago
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
Zacks·3mo ago